Recursion [RXRX] vs Zymeworks [ZYME] Detailed Stock Comparison

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

Zymeworks Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Recursion Pharmaceuticals Inc. wins in 7 metrics, Zymeworks Inc. wins in 11 metrics, with 0 ties. Zymeworks Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Recursion Pharmaceuticals Inc. Zymeworks Inc. Better
P/E Ratio (TTM) -2.44 3.79 Zymeworks Inc.
Price-to-Book Ratio 1.64 7.32 Recursion Pharmaceuticals Inc.
Debt-to-Equity Ratio 6.89 6.80 Zymeworks Inc.
PEG Ratio 0.04 0.05 Recursion Pharmaceuticals Inc.
EV/EBITDA -2.10 -20.40 Recursion Pharmaceuticals Inc.
Profit Margin (TTM) 4.45% -76.56% Recursion Pharmaceuticals Inc.
Operating Margin (TTM) -328.80% -1,755.55% Recursion Pharmaceuticals Inc.
Return on Equity -59.54% -26.72% Zymeworks Inc.
Return on Assets (TTM) -27.72% -14.29% Zymeworks Inc.
Free Cash Flow (TTM) $-380.44M $-35.36M Zymeworks Inc.
1-Year Return -35.98% 80.58% Zymeworks Inc.
Price-to-Sales Ratio (TTM) 24.83 18.46 Zymeworks Inc.
Enterprise Value $1.19B $1.73B Zymeworks Inc.
EV/Revenue Ratio 15.88 16.33 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) 59.62% N/A N/A
Revenue per Share (TTM) $0 $1 Zymeworks Inc.
Earnings per Share (Diluted) $-1.44 $-1.08 Zymeworks Inc.
Beta (Stock Volatility) 1.01 1.20 Recursion Pharmaceuticals Inc.
Short % of Float 34.94% 8.16% Zymeworks Inc.

Recursion Pharmaceuticals Inc. vs Zymeworks Inc. Stock Performance Analysis

Loading Price Chart...

RXRX
ZYME

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Recursion Pharmaceuticals Inc.4.44%-0.90%12.29%-2.95%-21.67%-21.67%
Zymeworks Inc.1.66%-2.80%-2.80%-1.52%-10.44%-12.62%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Recursion Pharmaceuticals Inc.-35.98%-64.69%-91.35%-89.94%-89.94%-89.94%
Zymeworks Inc.80.58%181.77%-36.88%76.00%76.00%76.00%

Performance & Financial Health Analysis: Recursion Pharmaceuticals Inc. vs Zymeworks Inc.

MetricRXRXZYME
Market Information
Market Cap i$1.85B$1.96B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i11,402,630626,460
90 Day Avg. Volume i12,390,473729,503
Last Close$3.29$23.26
52 Week Range$2.77 - $7.18$11.51 - $29.75
% from 52W High-54.18%-21.82%
All-Time High$42.81 (Jul 12, 2021)$59.03 (Jan 11, 2021)
% from All-Time High-92.31%-60.60%
Growth Metrics
Quarterly Revenue Growth6.82%-0.92%
Quarterly Earnings Growth6.84%-0.92%
Financial Health
Profit Margin (TTM) i0.04%-0.77%
Operating Margin (TTM) i-3.29%-17.56%
Return on Equity (TTM) i-0.60%-0.27%
Debt to Equity (MRQ) i6.896.80
Cash & Liquidity
Book Value per Share (MRQ)$2.14$3.60
Cash per Share (MRQ)$1.41$3.10
Operating Cash Flow (TTM) i$-371,808,000$-33,005,000
Levered Free Cash Flow (TTM) i$-208,521,744$-12,959,125
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Recursion Pharmaceuticals Inc. vs Zymeworks Inc.

MetricRXRX (Apr 26, 2026)ZYME (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i-2.443.79
Forward P/E i-4.1233.43
PEG Ratio i0.040.05
Price to Sales (TTM) i24.8318.46
Price to Book (MRQ) i1.647.32
Market Capitalization
Market Capitalization i$1.85B$1.96B
Enterprise Value i$1.19B$1.73B
Enterprise Value Metrics
Enterprise to Revenue i15.8816.33
Enterprise to EBITDA i-2.10-20.40
Risk & Other Metrics
Beta i1.011.20
Book Value per Share (MRQ) i$2.14$3.60

Financial Statements Comparison: Recursion Pharmaceuticals Inc. vs Zymeworks Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRXRX (2025)ZYME (2025)
Revenue/Sales i74.26M105.97M
Cost of Goods Sold i70.95MN/A
COGS % of Revenue i95.6%0.0%
Gross Profit i3.30MN/A
Gross Margin i4.4%0.0%
Research & Development i475.27M137.00M
Operating Income (EBIT) i-648.13M-92.54M
Operating Margin i-872.8%-87.3%
EBITDA i-559.38M-80.82M
EBITDA Margin i-753.3%-76.3%
Pre-Tax Income i-644.90M-79.75M
Pre-Tax Income % of Revenue i-868.5%-75.3%
Income Tax i-136,0001.38M
Income Tax % of Revenue i-0.2%1.3%
Net Income (Profit) i-644.76M-81.13M
Profit Margin i-868.3%-76.6%

Balance Sheet & Liquidity Metrics

MetricRXRX (2025)ZYME (2025)
Cash & Equivalents i743.29M41.16M
Total Current Assets i812.85M248.77M
Total Current Assets % of Revenue i1,094.7%234.8%
Total Current Liabilities i147.71M42.32M
Total Current Liabilities % of Revenue i198.9%39.9%
Long-Term Debt i56.21M14.80M
Long-Term Debt % of Revenue i75.7%14.0%
Total Shareholders Equity i1.13B268.50M
Retained Earnings i-2.08B-953.16M
Retained Earnings % of Revenue i-2,795.7%-899.5%
Property, Plant & Equipment i158.71M29.56M

Cash Flow Statement Comparison

MetricRXRX (2025)ZYME (2025)
Operating Cash Flow i-422.39M-40.00M
Operating Cash Flow % of Revenue i-568.8%-37.7%
Capital Expenditures i-6.47M-1.52M
Free Cash Flow i-380.44M-35.36M
FCF Margin i-512.3%-33.4%
Debt Repayment i-8.43MN/A
Common Stock Repurchase iN/A-41.70M

Short Interest & Institutional Ownership Analysis

MetricRXRXZYME
Shares Short i174.40M4.08M
Short Ratio i14.005.42
Short % of Float i34.94%8.16%
Shares Outstanding i528.18M75.19M
Float Shares i510.29M72.80M
% Held by Insiders i2.85%1.26%
% Held by Institutions i64.60%98.45%
% Held by Public i32.55%0.29%

Dividend Analysis & Yield Comparison: Recursion Pharmaceuticals Inc. vs Zymeworks Inc.

MetricRXRXZYME
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A